Inflammatory bowel disease (IBD), encompassing Crohn's disease and ulcerative colitis, presents a complex pathogenesis, making a complete cure elusive. Meanwhile, breast cancer ranks among the most prevalent cancers affecting women worldwide. Despite varying incidence rates, intriguing epidemiological studies suggest a potential link between IBD and breast cancer susceptibility. Some studies indicate a higher prevalence of breast cancer among individuals with IBD, while others find no such association, leading to a controversial debate. These observational studies are susceptible to confounding factors, making it challenging to establish a clear relationship.
Enter Mendelian randomization (MR), a powerful tool that utilizes genetic data to minimize the impact of confounding factors and assess causality. While epidemiological studies hint at a connection, a critical knowledge gap persists: no study has comprehensively explored the shared genetic drivers and immune-mediated pathways linking these diseases.
THBS3, an extracellular matrix protein, acts as an adhesion molecule, playing a crucial role in tissue remodeling, angiogenesis, and tumorigenesis. Its overexpression in multiple tumors is associated with poor prognosis. The role of THBS3-mediated immunoregulatory mechanisms in the context of IBD and breast cancer remains an intriguing mystery.
Our study hypothesizes that IBD may causally increase breast cancer risk through immune dysregulation, with shared genetic loci and the THBS3-mediated ceRNA network serving as critical hubs for cross-disease immune regulation. Our findings provide a compelling basis for early breast cancer screening in IBD patients.
We obtained data from the GWAS database, including European cases and controls for both IBD and breast cancer. MR analysis techniques, such as IVW, MR-Egger, WME, and WM, were employed to explore the causal link. We identified SNPs strongly associated with both diseases and performed linkage disequilibrium pruning. Instrument strength was evaluated using the F statistic, and causal estimates were obtained. Horizontal pleiotropy and heterogeneity were assessed to ensure the robustness of our findings.
Using MR, we analyzed genes associated with IBD and breast cancer, identifying common highly and lowly expressed genes. The Cancer Genome Atlas (TCGA) and Gene Expression Omnibus (GEO) databases were utilized to validate gene expression. Immunohistochemistry and RT-PCR confirmed elevated THBS3 expression in breast cancer tissues.
Immune infiltration analysis revealed a significant association between THBS3 and immune cell abundance in both IBD and breast cancer. Drug sensitivity analysis indicated a potential link between THBS3 expression and the half-maximal inhibitory concentration (IC50) of chemotherapeutic drugs. Molecular docking and dynamics simulations suggested a strong binding affinity between THBS3 and Rapamycin, highlighting its potential as a chemotherapy response indicator.
GSEA and GSVA analyses revealed that the Focal Adhesion and ECM Receptor Interaction pathways were associated with both IBD and breast cancer. The Proteasome pathway also showed a notable association. These findings suggest that THBS3 may play a crucial role in maintaining the dynamic balance of the tumor microenvironment by regulating ECM-related proteins.
Targeted therapeutic strategies for THBS3 could involve small-molecule inhibitors or RNA interference approaches. However, challenges related to off-target effects and systemic toxicity need careful consideration. Nanoparticle-based delivery systems may offer a promising solution to minimize these risks.
Our study confirms IBD as a risk factor for breast cancer, potentially linked to THBS3 expression and immune abnormalities. While our research has several advantages, including the first use of MR to analyze the impact of IBD on breast cancer and an in-depth analysis of underlying mechanisms, limitations exist. The research population is entirely of European descent, and our immunohistochemical and RT-PCR analyses were based on a small sample. MR cannot fully explain the interaction between genes and environmental factors like diet and lifestyle, which may influence the IBD-breast cancer relationship. Further research is needed to address these factors and expand the study population.
In conclusion, our study sheds light on the potential link between IBD and breast cancer, highlighting the role of THBS3 and immune dysregulation. However, the exact mechanisms remain elusive, necessitating further research to develop effective screening and prevention strategies for IBD patients.
Thought-provoking questions:
- Could THBS3-targeted therapies offer a breakthrough in managing breast cancer risk among IBD patients?
- How can we address the limitations of our study and improve our understanding of this complex relationship?
